Shopping Cart
- Remove All
- Your shopping cart is currently empty
D5B is an effective and selective PD-L1 inhibitor that has been modified with DBCO. It degrades PD-L1 in 4T1 and B16-F10 tumor cells with EC50 values of 5.4 μM and 6.2 μM, respectively. D5B can block the PD-L1/PD-1 interaction and exhibits antitumor activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | D5B is an effective and selective PD-L1 inhibitor that has been modified with DBCO. It degrades PD-L1 in 4T1 and B16-F10 tumor cells with EC50 values of 5.4 μM and 6.2 μM, respectively. D5B can block the PD-L1/PD-1 interaction and exhibits antitumor activity. |
In vitro | D5B (0-10 μM; 24 hours) degrades PD-L1 in 4T1 and B16-F10 tumor cells, with EC50 values of 5.4 μM and 6.2 μM, respectively. Additionally, D5B (0-5 μM; 48 hours) significantly reduces the abundance of PD-L1 on the cell membrane surface in IFN-γ treated and azide-labeled 4T1 and B16-F10 tumor cells. |
In vivo | Administered intravenously at a single dose of 5 mg/kg, D5B exhibits anti-tumor activity in mouse tumor models, with enhanced efficacy when combined with radiotherapy. (D5B refers to PCPGd@D5B nanoparticles). |
Molecular Weight | 983.15 |
Formula | C58H66N2O12 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.